Publicly subsidised smoking cessation medicines in times of COVID-19 in Australia: An interrupted time series analysis.
Dolly O BaliunasCoral E GartnerSamantha A HollingworthClair SullivanTracy A ComansJason D PolePublished in: Drug and alcohol review (2022)
There has been a differential change in the number of subsidised smoking cessation medicines supplied in Australia since the COVID-19 pandemic, with varenicline prescriptions largely within, and NRT patches largely lower than, expected ranges. The reasons for the apparent change in dispensing of subsidised smoking cessation medicines are unclear.